Generic drug sales increased 20 percent and sales of the anesthetic Lidoderm increased 16 percent. Stocks ended at $1.27 per share, above expectations of $1.18 per share.
Lower expectations were due in part to two patent lawsuit settlements.
More Articles on Anesthesia:
Tony Mira: Analyzing Anesthesiologists’ Investments in ASCs
Mylan’s Generic Anesthesia Drug Approved by FDA
Mission Hospital Renews Partnership With Asheville Anesthesia Associates
